| Adam H. Schechter |
President & CEO, Director |
$26.3M |
-$1.51M |
-5.43% |
Nov 11, 2024 |
| Glenn A. Eisenberg |
Executive Vice President |
$8.71M |
-$13.6M |
-61% |
Dec 2, 2024 |
| Brian J. Caveney |
EVP, Pres of ED, CMO & CSO |
$6.85M |
|
|
Mar 27, 2024 |
| Lance Berberian |
Evp, Cio & Cto |
$4.1M |
-$2.77M |
-40.3% |
Aug 5, 2024 |
| Jean Luc Belingard |
Director |
$4.03M |
|
|
Feb 6, 2024 |
| Thomas Pike |
Pres & CEO Clinical Business |
$3.57M |
|
|
Jan 9, 2023 |
| KerrII B. Anderson |
Director |
$3.27M |
-$791K |
-19.5% |
Jan 7, 2025 |
| Peter M. Neupert |
Director |
$2.88M |
|
|
Feb 6, 2024 |
| Garheng Kong |
Director |
$2.87M |
|
|
Feb 6, 2024 |
| Paul R. Kirchgraber |
CEO, Covance Drug Development |
$2.84M |
|
|
May 19, 2023 |
| Megan D. Bailey |
EVP, Pres, Central Labs & Intl |
$2.77M |
|
|
Nov 1, 2024 |
| Richelle P. Parham |
Director |
$2.12M |
|
|
Feb 6, 2024 |
| Dwight Gary Gilliland |
Director |
$2.07M |
-$241K |
-10.4% |
Dec 2, 2024 |
| Mark S. Schroeder |
EVP, Pres Diagnostics & COO |
$1.98M |
-$2.51M |
-55.9% |
Apr 1, 2024 |
| R. Sanders Williams |
Director |
$1.87M |
|
|
Feb 6, 2024 |
| Jonathan P. DiVincenzo |
EVP, Pres, Central Labs & Intl |
$1.61M |
-$108K |
-6.27% |
Mar 27, 2024 |
| Amy B. Summy |
EVP, Chief Marketing Officer |
$1.32M |
-$1.69M |
-56.1% |
Nov 22, 2024 |
| Sandra D. van der Vaart |
EVP, Chief Legal Officer |
$1.12M |
-$2.04M |
-64.6% |
Nov 21, 2024 |
| Akinbolade Oyegunwa |
Evp, Cio & Cto |
$1.09M |
|
|
Nov 1, 2024 |
| Jeffrey A. Davis |
Director |
$1.02M |
|
|
Feb 6, 2024 |
| Judith C. Seltz |
Evp, Chro |
$918K |
|
|
Mar 30, 2023 |
| Kathryn E. Wengel |
Director |
$724K |
|
|
Feb 6, 2024 |
| Julia Aijun Wang |
Chief Financial Officer, EVP |
$644K |
|
|
Dec 2, 2024 |
| Peter J. Wilkinson |
SVP, Chief Accounting Officer |
$598K |
-$498K |
-45.4% |
Apr 29, 2024 |
| Kirsten M. Kliphouse |
Director |
$506K |
|
|
Feb 6, 2024 |
| Anita Z. Graham |
Evp, Chro |
$449K |
|
|
Feb 6, 2024 |
| Paul Rothman |
Director |
$350K |
|
|
Jun 6, 2024 |